ImaginAb and Cyclotek Enter into Manufacturing and Distribution Agreement for CD8 ImmunoPET Agent in Australia
Inglewood, California, October 17th 2022 – ImaginAb, Inc., a global biotechnology company focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and radiopharmaceutical therapies (RPT) products, is pleased to announce the completion of a Master Services Agreement with Cyclotek, a leading radiopharmaceutical manufacturer in Australia and New Zealand, for the commercial manufacturing and distribution of […]